Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

New Discoveries and Updates on Cutaneous Adverse Drug Reactions Presented at the 24th World Congress of Dermatology, Milan, Italy, 2019

This is a preview of subscription content, log in to check access.

Notes

  1. 1.

    Niigata University Graduate School of Medical and Dental Sciences, Japan.

  2. 2.

    Lyon University Hospitals, France.

  3. 3.

    University of Toronto, Canada; Kyorin University School of Medicine, Japan.

  4. 4.

    Lyon University Hospitals, France.

  5. 5.

    Chang Gung University, Taiwan.

  6. 6.

    University of Toronto, Canada; University of Alberta, Canada; Autonomous University of Nuevo Leon, Mexico.

  7. 7.

    University of Toronto, Canada; King Fahad Medical City, Saudi Arabia.

  8. 8.

    King's College Hospital, London, United Kingdom.

  9. 9.

    University of Cape Town, South Africa.

  10. 10.

    University of Southampton, United Kingdom.

  11. 11.

    Duke-National University of Singapore Medical School, Singapore.

  12. 12.

    Paris-Est Créteil University, France.

  13. 13.

    All India Institute of Medical Sciences, India.

  14. 14.

    Shandong Academy of Medical Sciences, China.

  15. 15.

    University of Liverpool, United Kingdom.

  16. 16.

    Ravindra Nath Tagore Medical College, India.

  17. 17.

    King’s College London, United Kingdom.

  18. 18.

    University of California San Francisco, U.S.A.

  19. 19.

    Mackay Memorial Hospital, Taiwan.

  20. 20.

    University of Messina, Italy.

  21. 21.

    Université Libre de Bruxelles, Belgium.

  22. 22.

    Shandong Academy of Medical Science, China.

  23. 23.

    Harvard University, U.S.A.

  24. 24.

    University of Bologna, Italy.

  25. 25.

    Heinrich-Heine-University, Germany.

  26. 26.

    Yale University, U.S.A.

  27. 27.

    National Taiwan University, Taiwan.

  28. 28.

    Institut Universitaire du Cancer Toulouse-Oncopole, France.

  29. 29.

    Catholic University of the Sacred Heart, Italy.

  30. 30.

    Cornell University, USA.

  31. 31.

    University of Freiburg, Germany.

References

  1. 1.

    Olteanu C, Shear NH, Chew HF, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, et al. Severe physical complications among survivors of stevens-johnson syndrome and toxic epidermal necrolysis. Drug Saf. 2018;41:277–84.

  2. 2.

    Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, et al. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016;175:422–4.

  3. 3.

    Lew TT, Creamer D, Mackenzie J, Walsh SA. Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms. Br. J. Dermatol. England; 2015. p. 836–7.

  4. 4.

    Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128:985–96.

  5. 5.

    Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, et al. Interleukin-15 is associated with severity and mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017;137:1065–73.

  6. 6.

    Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol. 2019;80(670–678):e2.

  7. 7.

    Tridente A. Sepsis 3 and the burns patient: do we need Sepsis 3.1? Scars Burn Heal. 2018;4:1–7.

  8. 8.

    Koh HK, Chai ZT, Tay HW, Fook-Chong S, Choo KJL, Oh CC, et al. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: a cohort study of 176 patients. J Am Acad Dermatol. 2019;81:686–93.

  9. 9.

    Kirchhof MG, Wong A, Dutz JP. Cyclosporine treatment of drug-induced hypersensitivity syndrome. JAMA Dermatol. 2016;152:1254–7.

  10. 10.

    Tian XY, Liu B, Shi H, Zhao ZR, Zhou XP, Zhang T, et al. Incidence of adverse cutaneous drug reactions in 22,866 Chinese inpatients: a prospective study. Arch Dermatol Res. 2015;307:829–34.

  11. 11.

    Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States adults. J Invest Dermatol. 2016;136:1387–97.

  12. 12.

    Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80.

  13. 13.

    Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, et al. β-Lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. J Allergy Clin Immunol. 2018;141(235–249):e8.

  14. 14.

    Zhao Q, Alhilali K, Alzahrani A, Almutairi M, Amjad J, Liu H, et al. Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019;74:1533–48.

  15. 15.

    Wu X, Yang F, Chen S, Xiong H, Zhu Q, Gao X, et al. Clinical, Viral and genetic characteristics of drug reaction with eosinophilia and systemic symptoms (DRESS) in Shanghai, China. Acta Derm Venereol. 2018;98:401–5.

  16. 16.

    Li YY, Jin YM, He LP, Bai JS, Liu J, Yu M, et al. Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan. China. Sci Rep. 2016;6:35938.

  17. 17.

    Yue Z, Sun Y, Wang C, Yu W, Cao J, Bao F, et al. Amino acid variants of HLA-DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA-B*13:01. J Invest Dermatol. 2018;138:1101–6.

  18. 18.

    Liu H, Wang Z, Bao F, Wang C, Sun L, Zhang H, et al. Evaluation of prospective HLA-B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy. JAMA Dermatol. 2019;155(6):666–72.

  19. 19.

    Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, et al. The epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol. 2017;137:1240–7.

  20. 20.

    Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016;46:253–8.

  21. 21.

    Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46:594–600.

  22. 22.

    Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients–Treatment and outcome. Allergol Int. 2016;65:74–81.

  23. 23.

    Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, et al. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: a retrospective cohort study. J Am Acad Dermatol. 2019. pii: S0190-9622(19)32432-6.

  24. 24.

    Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18:654–62.

  25. 25.

    Sibaud V, Leboeuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26:427–43.

  26. 26.

    Ding F, Liu B, Wang Y. Risk of hand-foot skin reaction associated with VEGFR-TKIs: a meta-analysis of 57 randomized controlled trials involving 24956 patients. J Am Acad Dermatol. 2019;S0190–9622(19):30607–8.

  27. 27.

    Sibaud V, Tournier E, Roche H, Del Giudice P, Delord JP, Hubiche T. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity. Clin Exp Dermatol. 2016;41:34–7.

  28. 28.

    Balagula Y, Huston KB, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs. 2011;29:1114–21.

  29. 29.

    Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, et al. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016;50:79–89.

  30. 30.

    Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier P-P, Duru G, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134:1351–8.

  31. 31.

    Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(902–910):e2.

  32. 32.

    Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(455–461):e1.

Download references

Author information

The authors take full responsibility for drafting of this manuscript.

Correspondence to Roni P. Dodiuk-Gad.

Ethics declarations

Funding

No funding sources were used in the preparation of this manuscript.

Conflict of interest

Felix L. Chan, Neil H. Shear, Nidhi Shah, Cristina Olteanu, Rena Hashimoto, and Roni P. Dodiuk-Gad have no conflicts of interest that are directly relevant to the content of this study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chan, F.L., Shear, N.H., Shah, N. et al. New Discoveries and Updates on Cutaneous Adverse Drug Reactions Presented at the 24th World Congress of Dermatology, Milan, Italy, 2019. Drug Saf 43, 179–187 (2020). https://doi.org/10.1007/s40264-019-00880-9

Download citation